Shaping the Future of Oncology: Molecularly Distinct Cancer Therapies

Introduction

Cancer treatment has undergone a dramatic transformation in recent years, moving from broad cytotoxic chemotherapies toward molecularly precise strategies tailored to specific genetic, epigenetic, and proteomic vulnerabilities. The rise of targeted therapies, immuno-oncology, and multimodal approaches has already reshaped clinical practice. Yet, many cancers, particularly those harboring mutations long considered “undruggable”, remain resistant to available treatments. The next wave of cancer innovation centers on therapies that leverage molecular precision in novel ways, from protein degradation and stabilization to tumor-agnostic targeting and engineered immune cells.

By examining both broad mechanistic categories and specific drug candidates, this article provides a forward-looking perspective on how cancer therapy is being redefined.

Promising New Approaches to Cancer Therapies

Promising molecularly distinct cancer therapies are transforming cancer treatment by precisely targeting the unique drivers of tumor development, progression, and resistance, offering new hope for cancers that have historically been difficult to treat. By exploiting specific genetic mutations, protein interactions, or immune responses, these therapies improve treatment efficacy while minimizing off-target effects. Together, these innovative approaches promise to expand personalized treatment options and ultimately enhance patient survival and quality of life.

Several mechanistically distinct therapeutic classes under development are listed below, and stand out because of their unique mechanisms, and potential to expand treatment possibilities into previously untreatable cancers.

Tumor suppressor stabilization: New approaches aim to restore or stabilize tumor suppressor proteins that are commonly inactivated in cancers (e.g., p53). By reactivating their tumor suppressive functions, these therapies enhance intrinsic anti-cancer mechanisms such as cell cycle arrest, apoptosis, and DNA repair. Cancer cells exposed to these strategies face reactivation of growth control checkpoints and programmed cell death pathways.

Drug Examples:

APR-246 (Aprea Therapeutics)

• Mechanism: APR-246 is a small molecule prodrug converted intracellularly to methylene quinuclidinone (MQ), which covalently binds to cysteine residues in mutant p53 protein. This binding promotes refolding of mutant p53 into a wild-type-like conformation, restoring its DNA-binding and transcriptional activity.
• Effect on cancer cells: Functional p53 induces cell cycle arrest, senescence, and apoptosis in cancer cells with p53 mutations.

CGM097 (Novartis)

• Mechanism: CGM097 is a selective antagonist of mouse double minute 2 homolog (MDM2), an E3 ubiquitin ligase that ubiquitinates and promotes degradation of wild-type p53. By blocking the MDM2-p53 interaction, CGM097 stabilizes p53 protein levels. This mechanism is effective in cancers retaining wild-type p53 but overexpressing MDM2 for p53 inactivation.
• Effect on cancer cells: Up-regulated transcription of genes that induce cell cycle arrest and apoptosis.

 
Next-generation KRAS inhibitors: These inhibitors go beyond the KRAS G12C-targeting drugs by focusing on other KRAS mutations like G12D and G12V or acting broadly on KRAS or even pan-RAS proteins. KRAS is a small GTPase cycling between an active GTP-bound state and inactive GDP-bound state, regulating signaling pathways that promote cell proliferation. The earlier G12C inhibitors bind covalently to a new allosteric pocket called the switch-II pocket in the inactive GDP-bound form, locking KRAS in this inactive state. Next-generation inhibitors include compounds that bind allosterically or covalently, impair interaction with downstream effectors like RAF and PI3K, or create inhibitory complexes to sterically block effector interactions. Cancer cells respond initially with reduced signaling and viability, but resistance can develop through various mechanisms including switching between active/inactive states and activating compensatory pathways. These inhibitors hold promise for tougher-to-treat cancers such as pancreatic and colorectal tumors historically resistant to therapy.

Drug examples:

RMC-6236 (Mirati Therapeutics)

• Mechanism:Multi-selective tri-complex inhibitor that binds active GTP-bound forms of KRAS, HRAS, and NRAS (both mutant and wild-type).
• Effect on cancer cells:Blocks signaling in tumors driven by RAS mutations, inducing apoptosis and proliferative arrest, potentially overcoming resistance seen with earlier KRAS(G12C) inhibitors.

Sotorasib (Lumakras, Amgen)

• Mechanism:Selectively targets KRAS G12C mutant protein by binding its inactive GDP-bound form.
• Effect on cancer cells:Inhibits oncogenic KRAS signaling, causing tumor cell death. New research indicates it also flags cancer cells for immune killing when combined with immunotherapy.

 
Molecular glues: Small molecules that induce proximity between a target protein and an E3 ubiquitin ligase, facilitating the ubiquitination and proteasomal degradation of previously “undruggable” proteins. By forcing these unnatural protein-protein interactions, molecular glues can degrade crucial oncogenic factors driving cancer survival. Cancer cells initially undergo protein depletion leading to disrupted signaling or survival mechanisms. Resistance mechanisms may evolve through mutations that prevent protein-ligase binding or compensatory signaling activation.

Drug examples:

RC8 (Revolution Medicines)

• Mechanism:The small molecule covalently and selectively engages the mutant KRAS protein when it is in its active, GTP-bound “ON” state by recruiting cyclophilin A, which remodels to create a neomorphic surface interface that binds the KRAS mutant.
• Effect on cancer cells:This tricomplex formation sterically inhibits KRAS interaction with downstream effectors, thereby blocking the oncogenic signaling cascade.

BI-3802 (Boehringer Ingelheim)

• Mechanism: Involves selective degradation of the oncogenic transcription factor BCL6 through a unique process of drug-induced polymerization and subsequent ubiquitin-proteasomal degradation.
• Effect on cancer cells: Blocks repression of BCL6 target genes and anti-proliferative effects in cancer cells such as diffuse large B-cell lymphoma.

 
Cyclic peptides: Cyclic peptides affect cancer cells through multiple mechanisms including inducing apoptosis by triggering mitochondrial pathways and caspase activation, inhibiting protein kinases involved in cancer cell survival, and disrupting key transcription factors such as HIF-1 that regulate tumor adaptation to hypoxia. Recent molecular advances have enhanced cyclic peptides as cancer drugs by improving their stability, targeting ability, and tumor penetration. Innovations include peptide-drug conjugates that penetrate tumors better than antibody-based therapies, and the activation of transcellular transport mechanisms for deeper drug delivery into tumors.

Drug examples:

BT8009 (Byondis)

• Mechanism:A cyclic peptide-drug conjugate targeting Nectin-4 on tumor cells.
• Effect on cancer cells:Delivers cytotoxic payload specifically to cancer cells expressing Nectin-4, causing targeted cell death.

Sunitinib-mimetic cyclic peptides (experimental, various companies)

• Mechanism:Multi-targeted receptor tyrosine kinase (RTK) inhibitor. Inhibits cellular signaling by competitively binding to the ATP-binding site of receptor tyrosine kinases.
• Effect on cancer cells:Disrupts pathways involved in tumor angiogenesis, cell proliferation, and survival, leading to reduced tumor vascularization and enhanced cancer cell apoptosis.

 
Allogeneic CAR-NK therapies: Induced pluripotent stem cell (iPSC)-derived CAR NK cells, such as FT596, are engineered to express chimeric antigen receptors targeting cancer antigens on B-cell lymphomas and are being tested for solid tumors. These CAR NK cells mediate tumor cell killing via recognition of target antigens combined with innate NK cytotoxicity mechanisms including release of cytotoxic granules and cytokines. Cancer cells may respond by downregulating antigen or activating evasion pathways, but the innate features of NK cells provide a broader killing scope.

Drug examples:

FT516 (Fate Therapeutics)

• Mechanism:NK cells are genetically engineered to express a high-affinity, non-cleavable variant of the CD16a receptor (FcgammaRIIIa).
• Effect on cancer cells:Enhances the NK cells’ ability to perform antibody-dependent cellular cytotoxicity (ADCC). In ADCC, the NK cells recognize antibodies that have attached to cancer cells, leading to targeted killing of those malignant cells. The NK cells then release cytolytic granules and cytokines to destroy the tumor cells.

NKX101 (Nkarta Therapeutics)

• Mechanism:Allogeneic CAR-NK cells targeting CD19 in hematologic cancers.
• Effect on cancer cells:CAR-targeted killing of CD19-expressing cancer cells with reduced graft-vs-host risk.

 
G protein coupled receptor (GPCR) targeting (Antibody-Drug Conjugates (ADCs): These ADCs incorporate novel cytotoxic payloads and target GPCRs on cancer cells. GPCRs undergo constitutive or induced internalization upon ligand or antibody binding. This internalization is advantageous for ADCs, as it promotes effective uptake of the cytotoxic payload into target cells after antibody binding, resulting in cell death.  The antibody portion binds selectively to the cancer cell antigen, and upon internalization, the payload is released intracellularly to induce cell death through mechanisms like DNA damage or microtubule disruption. Advances aim to optimize targeting to reduce toxicity and improve payload potency. Cancer cells respond with apoptosis, though resistance can occur via antigen loss or drug efflux.

Drug examples:

DS-6157 (Daiichi Sankyo)

• Mechanism:DS-6157 is an ADC composed of a humanized anti-GPR20 antibody linked via an enzymatically cleavable tetrapeptide-based linker to a novel exatecan derivative (DXd), which is a topoisomerase I inhibitor. Upon antibody binding to GPR20, the ADC is internalized by tumor cells; lysosomal enzymes cleave the linker, releasing DXd. DXd inhibits DNA topoisomerase I.
• Effect on cancer cells:Induces selective cytotoxicity in GPR20-expressing in gastrointestinal stromal tumors cells by delivering the DXd payload, leading to tumor cell apoptosis and tumor shrinkage, with potential efficacy in patients resistant to tyrosine kinase inhibitors.

AZD0305 (AstraZeneca)

• Mechanism:AZD0305 consists of an anti-GPRC5D antibody conjugated to a potent cytotoxic payload. After binding to GPRC5D, internalization by multiple myeloma cells leads to intracellular release of the cytotoxic agent, triggering cell death of the target cells.
• Effect on cancer cells:Selectively kills multiple myeloma cells expressing GPRC5D, providing an option for patients refractory to other treatments and sparing healthy tissue due to targeted delivery.

 
Cancer vaccines: Designed to elicit strong antigen-specific immune responses, cancer vaccines introduce tumor-associated antigens or neoantigens to activate T cells and enhance anti-tumor immunity. Breakthroughs in RNA-based vaccines, innovations in delivery systems like layered nanoparticles enable rapid immune activation, and artificial intelligence and CRISPR technologies accelerate and refine vaccine design by optimizing neoantigen selection and immune targeting.

Drug Examples:

PRGN-3005 (Precigen)

• Mechanism: PRGN-3005 is a viral vector-based therapeutic vaccine delivering tumor neoantigens encoded within the vector to antigen-presenting cells (APCs). This process facilitates the presentation of neoantigen peptides on MHC molecules, priming and activating cytotoxic CD8+ T cells specifically against cancer cells harboring those neoantigens.
• Effect on cancer cells: The induced T-cell response recognizes and kills tumor cells expressing these mutated proteins.

UV1 (Ultimovacs)

• Mechanism: UV1 is a synthetic long peptide vaccine targeting telomerase reverse transcriptase (hTERT), a universal tumor antigen expressed in 85-90% of cancers. UV1 peptides are presented by APCs to CD4+ and CD8+ T cells, producing a sustained immune response to hTERT-expressing tumor cells.
• Effect on cancer cells: The immune activation leads to T-cell mediated tumor cell killing and immune system memory formation.

Looking Ahead: Landslide of Molecularly Distinct Cancer Therapies

The following table lists some additional approaches exemplifying emerging and innovative strategies reshaping cancer therapy by targeting unique molecular mechanisms and leveraging emerging technologies.

Conclusion

Finding novel molecular approaches to cancer therapy is critically important because cancer is a highly heterogeneous and adaptive disease that often becomes resistant to existing treatments. Targeted therapies are essential as they aim to precisely attack molecular drivers unique to cancer cells, sparing normal tissues and reducing side effects. This precision increases treatment efficacy and improves patients’ quality of life.

Moreover, cancer cells frequently develop resistance to drugs, which limits the long-term effectiveness of many standard therapies. Novel molecular approaches seek to overcome these resistance mechanisms by exploiting advanced knowledge of cancer biology, such as epigenetic regulation, inducing ferroptosis, or harnessing immune system components like complement modulation. By targeting multiple distinct pathways or integrating innovative technologies like logic-gated immune cells, these therapies can address tumor complexity and heterogeneity more effectively.

The continuous development of diverse molecular modalities, including gene silencing, oncolytic viruses, bispecific T-cell engagers, radiopharmaceuticals, and others, provides a growing arsenal to tailor treatments for individual patients and tumor types. This expansion of molecularly distinct strategies promises to improve outcomes in cancers that have been historically hard to treat and pave the way toward lasting remission and personalized oncology care in the future.